scholarly journals The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor‐α inhibitor

JGH Open ◽  
2019 ◽  
Vol 3 (3) ◽  
pp. 217-223
Author(s):  
Taketo Suzuki ◽  
Tsutomu Mizoshita ◽  
Satoshi Tanida ◽  
Naomi Sugimura ◽  
Takahito Katano ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Maintenance Therapy ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Remission Induction ◽  
Factor Α ◽  
Necrosis Factor

Mo1860 - High Fecal and Serum Tumor Necrosis Factor-α Levels are Associated with Non-Response to Infliximab in Patients with Ulcerative Colitis

2018 ◽  
Vol 154 (6) ◽  
pp. S-829
Author(s):  
Hadar Meringer-Milwidsky ◽  
Nitsan Maharshak ◽  
Yulia Ron ◽  
Henit A. Yanai ◽  
Sarit Cohen-Kedar ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor ◽  
Serum Tumor Necrosis

scholarly journals Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis

2015 ◽  
Vol 53 (3) ◽  
pp. 253-260
Author(s):  
T. Voiosu ◽  
Andreea Benguş ◽  
P. Bălănescu ◽  
Roxana Dinu ◽  
A. Voiosu ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Fecal Calprotectin ◽  
Mucosal Healing ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Factor Α ◽  
Necrosis Factor

AbstractBackground and Aims. Serum and fecal biomarkers have been used as noninvasive methods for assessing disease activity in ulcerative colitis. C-reactive protein, serum tumor necrosis factor-α and fecal calprotectin are among the most promising such biomarkers. However, their role in the management of ulcerative colitis patients remains to be clarified. We aimed to evaluate the accuracy of C-reactive protein, fecal calprotectin and tumor necrosis factor-α in detecting clinical and endoscopic activity and predicting disease outcome.Methods. A cohort of ulcerative colitis patients was prospectively evaluated for clinical and endoscopic disease activity using the Mayo score. Serum C-reactive protein and tumor necrosis factor-α levels were measured and a point-of-care method was used for determining Calprotectin levels.Results. Fifty-three patients with ulcerative colitis were followed for a median of 12 months. Fecal calprotectin and C-reactive protein levels were significantly higher in patients with clinically active disease at baseline, but only calprotectin levels correlated with endoscopic activity. Calprotectin values over 300 μg/g had 60% sensitivity and 90% specificity for detecting active endoscopic disease and 61% sensitivity and 89% specificity for predicting mucosal healing.Conclusion. Rapid calprotectin testing is a better predictor of mucosal healing than serum biomarkers and it could improve the management of ulcerative colitis patients by decreasing the need for invasive investigations.

Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis

Cytokine ◽  
2016 ◽  
Vol 79 ◽  
pp. 90-95 ◽  
Author(s):  
Trine Olsen ◽  
Renathe Rismo ◽  
Mona Dixon Gundersen ◽  
Eyvind J. Paulssen ◽  
Knut Johnsen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Infliximab Therapy ◽  
Factor Α ◽  
New Criterion ◽  
Necrosis Factor

scholarly journals Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

2015 ◽  
Vol 21 (11) ◽  
pp. 3282-3290 ◽  
Author(s):  
Enayatullah Baki ◽  
Philipp Zwickel ◽  
Anna Zawierucha ◽  
Robert Ehehalt ◽  
Daniel Gotthardt ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Real Life ◽  
Ambulatory Treatment ◽  
Factor Α ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document